Archive for January, 2021
A researcher from Tel Aviv University has developed a way to produce dairy products from yeast. Professor Tamir Tuller from the university’s Department of Biomedical Engineering is the researcher behind this innovative development. Tuller worked together with Dr. Eyal Iffergan, a food technology entrepreneur, to set up Imagindairy, a start-up company that plans to make cow’s milk using yeast.
This development comes at a time when researchers are working on finding substitutes for milk because dairy farming damages not only the environment but also human health.
Tuller explained that Imagindairy’s objective was to create milk that contained all the nutritional contents of cow’s milk along with a similar texture, aroma and taste. The only things excluded from the equation would be the damage caused to the environment during dairy farming and the suffering that cows go through during the dairy process.
These parameters will make Imagindairy’s cheese and milk products healthier than milk that is obtained from animals because the products will not contain somatic cells, lactose and cholesterol.
In his report, Tuller explained that the start-up also includes food experts and Strauss Company food engineers. For now, the researchers are working on leveraging the milk proteins from yeast to produce cheese using those proteins. Tuller explained that this was a long process of improvement, especially considering that the product is not similar to substitutes, such as nut milks (soy or almond milk, for example).
Tuller added that the company plans to manufacture dairy products through the introduction of yeast genomes, resulting in products similar to those derived from animals. Tuller and his lab have spent more than a decade exploring and specializing in the engineering and modeling of gene expression through the use of machine learning, computational modeling of molecular evolution and biophysical simulations. The models are then used to facilitate the manufacture of heterologous proteins more efficiently, which in turn makes them cheaper.
Tuller explained that the genome of each living creature is comprised of genes that contain an encoded formula for making amino acid chains which manufacture proteins. However, the genome also has information that ciphers gene expression. He explained that this was a complicated process involving protein creation.
Imagindairy has been working with Tel Aviv University’s technology transfer company, Ramot, in its efforts. Ramot CEO Keren Primor Cohen states that Tuller’s groundbreaking technology could revolutionize the dairy industry.
The study findings were reported in the “News Medical and Life Sciences” journal.
Aside from researching how to generate milk from yeast, another biotech company, CNS Pharmaceuticals Inc. (NASDAQ: CNSP), has placed its focus on finding solutions to the worldwide challenge of brain tumors. The company already has a drug candidate (Berubicin) undergoing clinical trials, which is giving patients with brain tumors hope that a treatment could soon be available.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Shares of AzurRx BioPharma Inc. (NASDAQ:AZRX) traded at a new 52-week high today of $1.39. So far today approximately 3.2 million shares have been exchanged, as compared to an average 30-day volume of 2.6 million shares.
AzurRx BioPharma Inc. share prices have moved between a 52-week high of $1.39 and a 52-week low of $0.37 and are now trading 242% above that low price at $1.27 per share.
AzurRx BioPharma Inc. (NASDAQ:AZRX) defies analysts with a current price ($1.27) 44.9% above its average consensus price target of $0.70.
AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, has begun its Phase 2b OPTION 2 extension study of MS1819. AZRX announced that the first two patients have been dosed in the extension study of MS1819, which uses immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The OPTION 2 extension phase design, which was recently announced by AzurRx, is designed to evaluate patients aged 18 years and older who have already completed the OPTION 2 crossover trial; the OPTION 2 extension study utilizes higher doses than those used in the OPTION 1 trial. The company announced that the two patients who have been dosed will continue to be treated for the duration of the next two weeks. “As expected, the Data Monitoring Committee (‘DMC’) remains supportive of our program with no safety concerns regarding the design and protocol of the study,” said AzurRx BioPharma chief medical officer Dr. James Pennington in the release. “Due to enrollment in the initial crossover trial being ahead of schedule, we are given an opportunity to thoroughly explore optimal doses and capsule types that will help guide our future development plans for MS1819 in a Phase 3 program. In the meantime, we will continue our preparation for a successful FDA meeting later this year.”
To view the full press release, visit http://ibn.fm/Vp2pS
About AzurRx BioPharma Inc.
AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Digital connectivity and tracing innovator Loop Insights is developing contactless, digital wallet-based disruptive services in an era defined by the COVID pandemic’s distancing protocols
- During 2020, as many businesses floundered, Loop recorded its most successful year ever by forging a variety of partnerships for government and retail solutions, consumer access to healthcare information, and the rebirth of select in-person events
- Loop provided venue tracing and informational services as the tech resource for two NCAA sports bubble events during the year and is helping the travel and film industry to similarly renew productivity with minimized concerns about viral infection
- Loop’s solutions are also providing disparate governments with the ability to work together with shared information on COVID-19 medical and security protocols while maintaining their own local authority through control of their data repositories
The year 2020 was a make-or-break period for many businesses as they scrambled to continue their operations during the COVID-19 pandemic. Decisions had to be made about staffing levels, policies to protect the health of employees and customers, and how to best connect with customers and the product supply chain as a result of efforts to reduce the risk of transmitting a contagion responsible for killing or debilitating millions of people (https://ibn.fm/smlZw).
Internet of Things (“IoT”) data connectivity innovator Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) is celebrating its “most successful year ever” after finding itself positioned with the right product and service at the right time to capitalize on the exponential growth of highly connected consumers online as a result of the pandemic.
“Throughout the year, my team and I have worked tirelessly to create products and solutions that would gain the trust of our partners … so that they could have the confidence necessary to bring this into their global customer opportunities,” Loop Insights CEO Rob Anson stated in a recap of the company’s progress (https://ibn.fm/Fvruj). “I am happy to report that we have accomplished this goal and as a result of these world-class partnerships, are now on the cusp of participating in global opportunities we never thought possible at the beginning of 2020.”
Loop has deployed its digital Wallet as part of the company’s venue management platform, which provides venue-based tracing, real-time customer engagement, and AI-driven insights. As demonstrated by Loop during its deployments at two NCAA venue bubbles, the company’s platform offers a number of real-world applications that can be applied to a number of industries, including live sports, entertainment, film, travel, and many others.
CEO Rob Anson also noted that a number of significant developments in 2020 will still have further implications for the company moving forward into 2021. Loop has existing partnerships with Amazon Web Services for networking with government leaders, two product partnerships with TELUS to promote its products, and an existing partnership with NTT DATA (a subsidiary of Nippon Telegraph and Telephone) that all offer significant potential for expansion. Additionally, the company’s partnership with Vend, has led to a number of retail opportunities through the company’s exposure to 25,000 stores in over 140 countries.
Loop’s contactless solutions are also being employed in its Digital Connect Health Platform, which was launched this month to streamline patient interaction with medical providers. Through a simple wallet pass, patients can easily check-in for appointments, receive updates on testing, and be notified in real-time about virus tracing and other critical health information all connected by a digital ID.
“The attempted implementation of wildly varying COVID-19 medical and security protocols, as well as, restriction policies by health officials and government leaders from around the world, has clearly demonstrated how divided government leaders have become by jurisdictional lines due to the lack of a single platform capable of providing uniformity and consistency in the application of policies,” Loop’s news release about the platform stated (https://ibn.fm/1OQSn). “Recognizing this breakdown, in conjunction with input from those same government leaders, Loop Insights developed the Digital Connect Health Platform to be capable of connecting Provincial and Federal systems while allowing Provinces to fully maintain their jurisdictional authority by managing their own internal data repositories.”
Loop’s ability to provide governments and the private sector with the means of connecting their current legacy and antiquated systems is “so revolutionary that it has attracted the attention of global technology companies and has positioned Loop for success within healthcare,” Anson stated.
For more information, visit the company’s website at www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, has announced that it will be hosting a virtual roadshow next month. The event is scheduled for 11 a.m. ET on Wednesday, Feb. 3, 2021. Trxade Group CEO Suren Ajjarapu will host the presentation, which will include an overview of the company’s business model and an outline of growth initiatives. The webinar will also include a question-and-answer session. The entire presentation can be accessed via webcast link or dial-in numbers. Those interested in the webcast can register before the event, then sign in to view the presentation on the day of the event. Those interested in listening to the presentation can call 1-844-512-2921 within the United States or 1-412-317-6671 internationally. Those calling in should dial in at least 10 minutes before the presentation begins. In addition, the webcast will be available for replay through Feb. 17, 2021, by calling 1-844-512-2921 within the United States or 1-412-317-6671; enter replay pin number 13714981. The webcast will also be available for 90 days on the IR section of the Trxade Group website.
To register for and view the full webcast, visit https://ibn.fm/Q7m5p
To view the full press release, visit https://ibn.fm/pdlVF
About Trxade Group Inc.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has announced a partnership with C.A. Fortune E-Comm, the online arm of C.A. Fortune, to offer WTER’s A88 family of beverages across various e-commerce platforms. The partnership is effective Jan. 21, 2021, and platforms include Amazon.com, Walmart.com, Kroger.com, Thrive.com, Boxed.com and zulilly.com among others. WTER is a producer of premium bottled alkaline water, flavor-infused waters, and CBD-infused products sold under the brand names Alkaline88(r), A88 Infused(TM), and A88CBD(TM) respectively. In the announcement, WTER noted that the C.A. E-Comm team includes account representatives, inventory specialists, content specialists and data analysts. These experts will assist in efforts to grow the Alkaline88 brand on various leading retailers’ online platforms; the C.A. E-Comm team will also support WTER with day-to-day marketing and promotional planning, troubleshooting pricing issues, a deep-dive performance analysis, optimized content development and invoice management. “We are committed to growing our brands across all channels and excited to partner with C.A. E-Comm to capture the booming demand in online grocery sales,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “Digital sales for consumer goods have surged during the pandemic, with channels reporting triple-digit growth for this segment. This partnership further strengthens our relationship with C.A. Fortune, who has been a vital partner in our journey to becoming a national lifestyle brand. Our entire A88 beverage line will be available for our customers on various e-commerce platforms of major retailers. This is an incredible opportunity with a team that has helped brands enhance their online sales since 2004. We believe this opportune partnership can help us capture new share in the growing e-commerce segment.”
To view the full press release, visit: https://www.cnw.fm/49XnH
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
- Consumers bracing for COVID’s impact into 2022 with what is being dubbed “homebody economy”
- Pandemic has led to demand spikes, changes in consumer supply and buying patterns
- WTER has seen significant market share growth; ideally positioned to continue to expand
A recent survey indicates that consumers in a post-pandemic environment are likely to be cautious in their buying habits, as many expect continued impact moving into 2020; survey respondents indicated an estimated 40% increase in intent to purchase online (https://cnw.fm/yrmni). (The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has an aggressive growth strategy that includes a direct-to-consumer, e-commerce platform— www.A88CBD.com — along with a compelling digital-marketing campaign, which place the company in a strong position in the post-COVID environment.
“Consumers continue to shift to online shopping across categories, with many consumers planning to shift almost completely online after COVID-19,” reported a recent McKinsey and Company survey. “Americans are trying new digital habits and intensifying usage of digital behaviors such as grocery delivery and restaurant delivery.”
These consumers are looking for both convenience and value as they search out new brands. While many Americans are eager to spend more time with family and friends, they are not eager to return to grocery stores and restaurants. What is being dubbed the “homebody economy” is expected to stick post-COVID. Around 53% of Americans believe their routines will not return to normal until well into 2021 or even later.
Major shifts in consumers’ online spending focus on small businesses and e-commerce. This was seen in consumers’ online shopping patterns during Cyber Monday 2020 (with an increase in 15.1% from 2019), Small Business Saturday (with 30.2% growth) and Sunday (23.7% growth). Consumers are also focusing their purchases on groceries and health and wellness products (https://www.cnw.fm/oci3Q).
WTER looks to be well positioned to benefit from the new buying patterns. The top bulk-alkaline-water brand is committed to strengthening its presence in the e-commerce and online grocery shopping spaces as the demand for flavored waters, sustainable packaging and CBD are leading in health, wellness and lifestyle trends. The company has two online sites: one for CBD-infused products — www.A88CBD.com — and one for its flagship beverage products — www.TheAlkalineWaterCo.com.
“The pandemic has led to demand spikes and changing consumers supply and buying patterns, which we believe have finally begun to normalize,” WTER CEO Ricky Wright stated during the company’s November earnings call (https://cnw.fm/QQ3BZ). Wright also noted that the company had implemented aggressive promotional spending over the summer, resulting in increased market share.
“According to the total U.S. all-sales channels Nielsen’s report dated October 3, our flagship brand has been the fastest-growing, non-flavored, value-added water of the top 10 brands over the last 13-, 26- and 52-week periods,” he said. “Per Nielsen’s over the last 26 weeks, our brand has grown 17.7% compared to the category growth of a negative 0.3%. Over the previous 13 weeks, our retail sales have exceeded our quarterly average. And we’re robust — 23.2% more than double the category growth. In the last 26 weeks, we have also gained roughly 0.4% market share. This is equivalent to almost $8 million in annual retail sales. During the same period our top selling SKU has become one of the top 10 in the value-added water category in the entire country. We remain the only top 10 value-added water that has grown double digits in every four-week period since January.”
As one of the fastest growing alkaline water companies in the United States, WTER has continued to expand its brand. The company was able to enter the grocery and supermarket channel and provide products in more than 70,000 retail locations nationwide, including Walmart, Kroger, Albertsons, Safeway and Publix. Several single SKUs have also been introduced to these grocery stores. In addition, WTER is pursuing distribution to convenience stores, drugstores and specialty retail channels. Due to COVID, these stores have aligned their merchandise to include healthier, convenient items.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. Additionally, in 2020, the company launched its A88CBD Infused line of ingestible and topical products, including its CBD water.
For more information, visit the company’s websites at www.TheAlkalineWaterCo.com and www.A88CBD.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI’s innovative Ultra Shear Technology(TM) (“UST”) platform to strengthen the effectiveness of SinuSys Corp’s lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI’s UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later this year. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology services to the worldwide biotechnology, biotherapeutics and other industries. SinuSys Corporation is a medical device company focused on developing new therapies to improve the sinus health of patients. “Our patented UST platform is a unique breakthrough for nanoemulsification processing designed to resolve multiple substantive problems facing manufacturers of therapeutic drugs, nutraceuticals, and other products containing hydrophobic (water repelling) active ingredients that are at best poorly soluble in water,” said PBI chief science officer Dr. Alexander V. Lazarev in the press release. “Poor water solubility results in lower absorption rates and requires much higher loading of the active compounds into products to achieve targeted dosing and bioavailability of active ingredients for the patient. Unfortunately, poor water solubility also carries overdosing risks in conventional emulsions due to oil and water phases further separating and leading to non-uniform drug distribution. Scientific publications have demonstrated that hydrophobic active ingredients manufactured into high-quality nanoemulsions with droplet sizes of less than 100 nanometers can facilitate increased absorption and bioavailability while lowering doses and improving controlled release. This should result in better quality products and treatment experiences for the patient, with overall reduction in product costs.”
To view the full press release, visit http://ibn.fm/D3Nw6
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
A team of researchers from the University College London has demonstrated how small magnetic nanoparticles can be used to improve cancer treatment. Those nanoparticles can transport chemo drugs to cancer cells while also generating a minimal heating effect once stimulated through the use of an alternating external magnetic field.
The combination of chemotherapy and particle-mediated heat treatment brings about synergistic effects in the elimination of cancer cells. This proposes that the technology may be a useful tool in the fight against cancer.
The nanoparticles are made from iron oxide, which make them magnetic. These particles can be stimulated to generate a mild heating effect by using an alternating magnetic field. This mild rise in heat warms nearby cells to nearly 42º Celsius. While cancer cells die when exposed to this heat, healthy cells in an individual’s body can withstand the rise in temperature. The method is minimally invasive as the magnetic field can be directed at the site of the tumor and applied outside the individual’s body.
As mentioned above, the particles can deliver chemotherapy drugs to a tumor in an individual’s body, which helps restrict the tumor’s exposure to healthy tissues in other parts of the body. The particles have a polymer coating, which prevents them from releasing their drug until they have been absorbed in the lysosomes found in the cancer cells. The lysosomes’ acidity causes the particles’ polymer coating to disintegrate, thus allowing it to release the drug and bringing about the elimination of cancer cells. It should be noted that the coating also releases the drug when there is a rise in heat.
Thus far, researchers have tested the nanoparticles with various types of cancer cells that have been grown in the lab. The researchers discovered that delivering chemotherapy drugs, in particular doxorubicin, a common chemotherapy drug, while applying heat simultaneously resulted in synergistic effectiveness.
Nguyen TK Thanh, a researcher participating in the study, explained that the study demonstrated the huge potential of combining heat treatment delivered through magnetic nanoparticles with chemotherapy treatments. She noted that while this combination of therapy had already been approved for the treatment for rapidly growing glioblastomas, the recent study findings propose that the treatment has the potential to be used more extensively as a therapy that fights against cancer.
She added that the therapy could also be used to decrease the side effects of chemotherapy on an individual by making sure it targeted cancer cells rather than healthy tissue in an individual’s body. However, more pre-clinical tests need to be conducted to explore this option.
Many other exciting developments are coming to light within the biomedical sector. For instance, TumorGenesis, a subsidiary of Predictive Oncology (NASDAQ: POAI), is working on a novel way to grow tumors within a lab without using mice or rats in the process. This technique will ease the task of studying the biomarkers of various cancers.
NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
iClick Interactive Asia Group Limited (NASDAQ:ICLK) traded today at a new 52-week high of $14.16. Approximately 366,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares.
iClick Interactive Asia Group Ltd is an independent online marketing and enterprise data solutions provider in China. It serves as an integrated cross-channel gateway that provides marketers with innovative and cost-effective ways to optimize their online marketing efforts throughout their marketing cycle and achieve their branding and performance-based marketing goals. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives majority revenue from PRC and also has a presence in Hong Kong and other countries.
iClick Interactive Asia Group Limited (NASDAQ:ICLK) is currently priced 24.5% above its average consensus analyst price target of $10.14.
Over the past year, iClick Interactive Asia Group Limited has traded in a range of $3.01 to $14.16 and is now at $13.43, 346% above that low.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today reported the successful results from its partnership with KANS, an innovative Chinese cosmetic and beauty brand under Shanghai Chicmax Cosmetics Co., Ltd. (“Chicmax Group”). KANS saw a surge in its online consumer retention rate to 86% and purchase rate to 42.7% within the one-month period that it utilized iClick’s Enterprise Solutions. “Helping prestigious brands like KANS that operate in highly competitive industries achieve remarkable breakthroughs and business expansion is core to iClick’s mission,” iClick CEO and Co-Founder Jian “T.J.” Tang stated in the news release. “We are proud to have helped KANS further expand its online marketing capabilities. With such a strong demonstration of the power of iClick’s solutions, I believe we are well positioned to replicate the success to more companies in China’s booming cosmetics industry. Brands increasingly recognize the value iClick can provide in maximizing customer lifetime value, and we will remain focused on providing even more powerful solutions as we further develop our Integrated Enterprise and Marketing Cloud Platform.”
To view the full press release, visit https://ibn.fm/0XAjq
About iClick Interactive Asia Group Limited
iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe. For more information about the company, please visit ir.i-Click.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- CYBN partners with pioneer company focused on exploring, quantifying the human mind
- Innovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disorders
- Innovative technology opens new frontier in psychedelic therapeutics
Cybin (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is partnering with neurotech pioneer HI, LLC dba Kernel to quantify brain activity in real time during psychedelic experiences (https://ibn.fm/3AG5G). CYBN plans to do this by leveraging Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work.
“Access to Kernel’s innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction,” said Cybin CEO Doug Drysdale. “Currently, clinical investigators rely on limited subjective information from patients. The ability to collect quantitative data from our sponsored drug-development programs is potentially game changing in terms of our ability to measure where psychedelics work in the brain in real time, and how we ultimately design our future therapeutics.
“We are delighted to partner with Kernel to study the utility of Flow in sponsored clinical settings,” he continued. “This new cornerstone component of our sponsored clinical programs follows a record-setting capital raise, listing on the NEO Exchange and the acquisition of Adelia Therapeutics Inc., which added significant scientific capabilities, novel molecules, delivery mechanisms and intellectual property.”
In announcing the agreement, Cybin noted that the absence of the data that this partnership may provide has been a limitation in the progression of new molecules targeting neurological disorders. “Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal brain activity before, during and after a psychedelic experience, enabling quantification of what was previously subjective self-reporting,” said the company, noting that the Kernel technology is unique among brain-scanning technologies and is the first commercially scalable time-domain functional near-infrared spectroscopy system.
Based in Los Angeles, Kernel is comprised of ia team of neuroscientists, physicists, engineers, programmers, and experiment and operations experts focused on exploring and quantifying the human mind. The Kernel Flow is a head-worn, scalable, noninvasive neuroimaging system that leverages time-domain functional near-infrared spectroscopy, widely recognized as a gold standard optical method for detecting hemodynamics of the cerebral cortex.
Compared to traditional near-infrared spectroscopy devices, time-domain systems obtain richer brain signals by applying light in short pulses and precisely capturing the arrival time distribution of scattered photons from each pulse. Cybin plans to use Flow measurements as analogues of local neural activity during psychedelic experiences; the company anticipates that the quantitative measurements provided by Flow could enhance the development, delivery and scaling of its psychedelic therapeutics.
As part of the agreement, Cybin plans to take delivery of Flow in Q2 2021 and will then undertake sponsored studies in a range of clinical conditions. The company will use information, data and insights collected by Flow technology in the design of future clinical studies.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
TORONTO , Jan. 20, 2021 – Canopy Rivers Inc. (” Rivers ” or the ” Company “) (TSX: RIV) (OTC: CNPOF) today filed and mailed the management information circular (the ” Circular “) and related materials in connection with the special meeting (the ” Meeting “) of shareholders to be held virtually on February 16, 2021 at 10:00 a.m. ( Toronto time).
In light of the ongoing coronavirus pandemic and to mitigate against its risks, the Meeting will be held in a virtual only format via live audio webcast, available to all stakeholders at http://web.lumiagm.com/261351529 , password “canopy2021” (case sensitive). During the audio webcast, shareholders will be able to hear the Meeting live, and registered shareholders and duly appointed and registered proxyholders will be able to submit questions and vote while the Meeting is being held.
At the Meeting, shareholders will be asked to consider and, if deemed advisable, to pass a special resolution approving the previously announced plan of arrangement (the ” Transaction “) with Canopy Growth Corporation (” Canopy Growth “) (TSX: WEED, NASDAQ: CGC), pursuant to which Rivers will transfer three portfolio assets to Canopy Growth in exchange for $115 million in cash, 3,750,000 common shares 1 in Canopy Growth, and the cancellation of all the multiple voting shares (” MVS “) and subordinate voting shares (” SVS “) of Rivers held by Canopy Growth. As part of the Transaction, the Company will also change its corporate name to “RIV Capital Inc.”
In addition, Rivers is pleased to announce that on January 14, 2020 , it was granted an interim order by the Ontario Superior Court of Justice (Commercial List) (the ” Court “) authorizing various matters, including the holding of the Meeting and the mailing of the Circular.
The Company’s board of directors, other than certain conflicted directors (the ” Board “), unanimously approved the Transaction following a unanimous recommendation of a special committee, which was composed of directors independent of Canopy Growth, TerrAscend Corp. (” TerrAscend “) and management of Rivers. Both the special committee and the Board determined that the Transaction is fair to, and in the best interests of, the Company and unanimously recommend that shareholders vote in favour of the Transaction at the Meeting.
Benefits to Rivers Shareholders
Rivers believes the Transaction will propel the Company to its next phase of growth. The Company believes the Transaction will provide the following benefits, among others:
- Enables the Company to access new investment opportunities: Upon completion of the Transaction, the Company will be in a position to comprehensively re-evaluate its business and investment strategy and pursue previously unavailable opportunities, and in particular, investments in, or acquisitions of, opportunities in the U.S. market. As such investments or acquisitions may be inconsistent with the policies of the TSX, the Company is initiating the process to de-list from the TSX and list its securities on a stock exchange that does not prohibit such investments or acquisitions.
- Unlocks value for the Company: The Transaction allows the Company to unlock and realize the value of the TerrAscend exchangeable shares, which have significant liquidity restrictions and the value of which has not been adequately reflected in the Company’s share price, as well as its interest in Les Serres Vert Cannabis Inc., a private company for which there is no published market.
- Provides significant value and liquidity for the Company: The consideration payable by Canopy Growth pursuant to the Transaction is comprised of cash and highly liquid securities, which provides the Company with significant value and liquidity at a price that may not be available in the short to medium term in the absence of the Transaction, particularly in an uncertain economic and market environment. The Company will also have significant capital to pursue potential material investments in, or acquisitions of, established operating businesses in the U.S. cannabis market, many of which continue to experience uncertain and constrained access to capital.
- Eliminates the Company’s dual-class share structure: Upon closing of the Transaction, the Company and its shareholders will derive a number of benefits associated with the elimination of the Company’s dual class share structure, including that:
- shareholders will have a vote that is proportionate to their relative economic interest in the Company; and
- the Company’s shares will be more attractive for purposes of raising capital or as an acquisition currency.
Meeting Materials
Shareholders should refer to the Circular and related materials for detailed instructions on how to vote and participate at the Meeting. The Circular also contains important information regarding the Transaction, and a summary of the events leading up to the Transaction, including the reasons that led the Board to determine that the Transaction is fair to Rivers and in the best interest of the Company. The Circular and related materials are available on the Company’s profile at www.sedar.com .
Shareholders can also view the Transaction details in a presentation prepared by the Company, available at www.canopyrivers.com/investors .
Meeting Details
The Transaction requires the approval of at least (a) two-thirds of the votes cast by both: (i) Canopy Growth as the holder of all of the MVS; and (ii) Rivers shareholders that hold SVS, and (b) a simple majority of the votes cast by holders of SVS, excluding the votes attached to the SVS held by Canopy Growth. Canopy Growth has agreed to vote all of its MVS and SVS in favour of the Transaction.
Funds managed by JW Asset Management, the Company’s largest holder of SVS, and each of the Company’s directors and executive officers, which in aggregate represent approximately 24.5% of the outstanding SVS, excluding the SVS held by Canopy Growth, have entered into voting support agreements agreeing to vote their SVS in favour of the Transaction.
Shareholders who are unable to virtually attend the Meeting are encouraged to complete, sign, date and return the form of proxy or voting instruction form provided with the meeting materials so that as many shareholders as possible are represented at the Meeting.
For any questions or assistance with voting their proxies, shareholders should contact Kingsdale Advisors, the strategic shareholder advisor and proxy solicitation agent, by telephone at 1-800-749-9052 (416-867-2272 for collect calls outside of North America ) or by email at contactus@kingsdaleadvisors.com .
About Canopy Rivers
Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 17 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies. Our mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with our portfolio, we are helping build the cannabis industry of tomorrow, today.
Forward Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. To the extent any forward-looking information in this news release constitutes “financial outlooks” within the meaning of applicable Canadian securities laws, the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions, and forward-looking information in this news release includes, but is not limited to, information and statements regarding: whether and when the Transaction will be consummated; the anticipated benefits of the Transaction, the Company’s expectation that the Transaction will significantly strengthen the Company’s capital and liquidity position, the anticipated cash proceeds from the Transaction net of the associated tax liability and transaction costs, the anticipated benefits associated with the elimination of the Company’s dual class share structure; the attractiveness of the Company’s shares as acquisition currency following the Transaction; the price and liquidity of the Canopy Growth common shares; the Company’s intention to invest, acquire and/or merge with operating U.S. cannabis companies and the value to be derived therefrom; the Company’s belief that operating businesses in the U.S. cannabis market experience uncertain and constrained access to capital; the possibility that the Company may de-list from the TSX following completion of the Transaction and list its securities on a stock exchange that permits investments in and/or acquisitions of U.S. cannabis companies; the anticipated timing of the Meeting and the requisite shareholder approvals to be obtained at the Meeting; the Company obtaining and/or satisfying customary approvals and conditions, including court approval for the Transaction; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein.
Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the parties’ ability to consummate the Transaction; the ability to receive, in a timely manner and on satisfactory terms, all necessary regulatory, court, shareholder, and other third party approvals; the ability of the parties to satisfy, in a timely manner, all other conditions to the closing of the Transaction; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, stock exchanges, lenders, employees and competitors; the diversion of management time on the Transaction; assumptions concerning the Transaction and the operations and capital expenditure plans of the Company following completion of the Transaction; credit, liquidity and additional financing risks for the Company and its investees; stock market volatility; regulatory and licensing risks; changes in cannabis industry growth and trends; changes in the business activities, focus and plans of the Company and its investees and the timing associated therewith; the Company’s actual financial results and ability to manage its cash resources; changes in general economic, business and political conditions, including challenging global financial conditions and the impact of the novel coronavirus pandemic; competition risks; potential conflicts of interest; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; changes in the global sentiment towards, and public opinion of, the cannabis industry; divestiture risks; competition risks; and the risk factors set out in the Circular and Canopy Rivers’ annual information form dated June 2, 2020 , filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com .
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
|
______________________
|
|
1 In the event that certain rights of first refusal in respect of the Company’s common equity interest in Les Serres Vert Cannabis Inc. are exercised, the number of shares issued by Canopy Growth to Rivers in connection with the Transaction would be reduced by approximately 103,000 shares, and in lieu, the Company would receive cash consideration of approximately $3.4 million from a third party.
|
- SRAX announces blockchain pioneer, digital media veteran Lou Kerner as CEO of BIGtoken
- BIGtoken, a data marketplace that allows users to own and earn from their data, creates data sets that can be accessed by marketers for a fee
- BIGtoken to be spun off into its own publicly-traded company through definitive agreement with Force Protection Video Equipment Corp.
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, recently announced that Lou Kerner – a prominent digital media expert and cryptocurrency pioneer – will be appointed Chief Executive Officer of BIGtoken, a wholly-owned subsidiary of SRAX.
BIGtoken, a data marketplace that allows consumers to earn from the use of their data while creating data sets accessible to marketers for a fee, has recently entered into a definitive agreement with Force Protection Video Equipment Corp. (OTC: FPVD). The transaction will allow SRAX to receive 88.9% of the issued and outstanding shares of FPVD in exchange for 100% of the shares of BIGtoken and, when completed, FPVD will be renamed to BIGtoken Inc. with Mr. Kerner as CEO.
“Lou has been working with data and internet startups his entire career. He has a detailed understanding of blockchain and how it is applied to augment business applications,” said SRAX CEO Christopher Miglino (https://ibn.fm/c15im). “Blockchain will play a big part in the future of consumer identity and privacy and we have a shared vision with Lou on what this will look like. Not only is Lou a technology expert, but his knowledge of the capital markets will be a significant asset to BIGtoken as the company is uplisted to a nationally listed exchange.”
Mr. Kerner started his career at Goldman Sachs as a Wall Street analyst with a focus on media companies before transitioning to operating technology companies. His first role as CEO was at The .tv Corporation International – a company that operates domain registry services for websites using the .tv domain extension. Following the acquisition of .tv by Verisign in 2001, Mr. Kerner became the CEO of Bolt Media, the dominant social media company prior to MySpace. After his tenure at Bolt, Mr. Kerner became an angel investor and producer of Wall Street-style reports on companies like Facebook before launching a small VC fund in 2012 and joining Flight Ventures – a venture capital firm focused on tech companies based in Israel.
Since 2017, Mr. Kerner has been an active analyst, investor, and advisor in the cryptocurrency industry and is currently one of the most followed authors on Medium. He advises many companies in the space that include the Blockchain Coinvestors fund, the Casper protocol, Props – an SEC-approved loyalty program token, and Silver Castle – an institutional-grade digital asset manager. He is also a partner in an AngelList Syndicate that actively invests in crypto projects in addition to being the founder of CryptoMondays – the largest crypto-focused group on the Meetup social network with chapters in over 50 cities across the world.
“As the world continues to move to ensure greater internet privacy for consumers, BIGtoken is well-positioned to help brands, media companies, research organizations, and political campaigns efficiently reach consumers via compliant ad targeting and surveys,” said Mr. Kerner. “I further believe BIGtoken will greatly benefit by fully embracing crypto as an alternative reward for our growing consumer base.”
SRAX Inc. is a digital marketing and consumer data management technology company that helps companies unlock insights that reveal core consumers and their characteristics across multiple marketing channels. Soon to be spun off into its own publicly-traded company, SRAX’s BIGtoken platform allows internet users to own and earn from their data while creating valuable data sets that can be accessed by marketers for a fee.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited investors for the issuance and sale of approximately 2,200,000 common stock shares at $1.00 per share; the registered direct offering, priced at-the-market following Nasdaq rules, will result in gross proceeds of $2.2 million for the company. Predictive Oncology plans to use the net proceeds from the offering for working capital purposes. In addition, POAI agreed to issue unregistered warrants to the investors to purchase up to 1,100,000 additional shares of common stock. The company noted that the warrants have an exercise price equal to $1.00 per share and are exercisable upon issuance with an expiration date five and one-half years from the issuance date. POAI’s offering is expected to close on or about Jan. 21, 2021, pending customary closing conditions.
To view the full press release, visit: https://ibn.fm/acc6f
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Colorado Springs is home to a small but growing community of electric vehicle (“EV”) drivers. The city boasts close to 2,300 electric vehicles, and according to projections, the number of EVs is expected to explode in the next two to three years, says Khaled Salem, Distributed Energy Strategies engineer supervisor at Colorado Springs Utilities. In anticipation of this influx of electric vehicles in the coming years, Utilities is evaluating where it can install and maintain EV charging stations.
By all indications, more and more Americans are expected to buy EVs over time. Although they can be quite expensive, electric cars are becoming more affordable, with industry experts projecting that they will be as cheap as, or even cheaper than, internal combustion engine vehicles by 2025. As EV makers introduce more models to the market, especially fully electric versions of the SUVs and pick-up trucks that Americans love, EV adoption is sure to increase.
Jillian Jaeger, manager of the city’s Electric Vehicle Readiness Plan, says Colorado is projected to have anywhere from 90,000 to 130,000 EVs by 2030. According to Colorado Springs Utilities manager of Energy Planning and Innovation, Michael Avanzi, Utilities initially projected residents would buy 50,000 to 300,000 EVs over the next 30 years, but that number is now expected to be much higher.
As such, the city and Utilities are working on the Electric Vehicle Readiness Plan to project how many cars the city can expect over time and identify locations that most need charging stations, among other issues. At the moment, Colorado Springs has close to 100 public charging stations, most of them provided by third-party vendors. With the number of EVs in the city expected to explode over the years, Colorado Springs may need between 7,000 and 10,000 charging stations by 2020, reports Jaeger.
These stations will be of great help to people who cannot charge their vehicles at home and don’t have access to a private charging option. Additionally, Jaeger says, Utilities wants to provide charging stations for long-distance travelers. Salem adds that Utilities would like to build some of these new charging stations, provide the electricity to charge EVs and manage the stations. Since the company is owned by the City of Colorado Springs, it could gain a market advantage by passing the cost of service down to the customers.
Salem says that if the Colorado Springs City Council approves the plan, Utilities could start building new charging stations in the latter half of 2022.
In other news, Net Element (NASDAQ: NETE), a leading financial technology company, plans to complete a merger with Mullen Technologies Inc., a manufacturer of electric vehicles based in California.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Psychedelics seem to have gotten quite a boost last year when Oregonians and DC voters voted to decriminalize psychedelics. While some analysts propose that this is only the beginning for the market’s growth, and that it will be similar to that of the cannabis market, this analysis has no data to its claim.
It should be noted that apart from their legality, the two substances have little in common. Comparing psychedelics to marijuana is also difficult, considering psychedelics are made up of hundreds of molecules, plants and substances while marijuana is encompassed in one plant genus.
Even an individual describing a psychedelics company would need to be more specific because the company is not likely to be testing out or experimenting with every psychedelic substance that exists. It could be psilocybin, ketamine or even LSD.
Additionally, a more exact comparison for the psychedelics industry would be the biotech industry, as both industries work with and modify different organisms with the intention of creating commercially viable products.
It is through testing and research that biotech companies have been able to develop life-saving vaccines, gene therapy and antibiotics. In the same way, psychedelic firms are researching, testing out and developing treatments for addiction, post-traumatic stress disorder (“PTSD”), depression, anxiety and other neurological-related conditions that do not currently have cures.
While it cannot be denied that marijuana does have the potential to and sometimes has served as a treatment for particular mental health conditions such as PTSD and anxiety, marijuana has not been able to infiltrate Big Pharma and biotech as a whole.
In addition to this, despite cannabis being legal in some form in almost every state in the country, both the medical community and the FDA have not been as willing to offer their support to the industry.
This is in contrast with the psychedelics industry, which has not only received support from the FDA but has had psychedelic substances such as psilocybin and MDMA, which are being tested as treatment for various mental health conditions, actual receive breakthrough therapy designations.
This is because psychedelics provide hundreds of different molecules that can be tested and developed in the same way that Big Pharma and biotech companies develop, test out and manufacture products that are distributed in the market. With the right product in this industry, a company may earn more than 20 times the returns from one product in the market.
Apart from this, estimates show that in five years, the treatment for addiction will be valued at roughly $50 billion, the treatment market for PTSD will be worth over $7 billion, and the depression and anxiety treatment market will be worth nearly $20 billion.
Most of the research that is currently being done in psychedelics focuses on the above markets, which shows that the psychedelics industry has the potential to not only control a huge chunk of the market share but also control them as a whole if the cannabis industry does not step up. This may be the case if one considers that these conditions currently do not have reliable cures, and psychedelic research has made significant strides in finding treatments that manage the said conditions.
Many companies are jumping into the functional mushrooms and psychedelic-medicines sectors. For instance, Cybin Inc. (NEO: CYBN) is now marketing several supplements made from non-psychedelic fungi.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Creatd (NASDAQ: CRTD), a proprietary technology platform for creators of all types, announced the release of the first of a series of updates to its Vocal platform technology. The enhanced design and functionality updates are focused on increasing creator discoverability and enriching the user experience. The company noted that the platform updates should also drive continuing growth in conversions from freemium creators to premium Vocal+ subscribers. The initial update was unveiled last week and features a more intuitive user experience for Vocal’s creators and audiences as well as new community-specific metrics that highlight the health, safety and user volume of both the creators and platform communities. The Vocal platform currently has more than 850,000 creators on the freemium tier, with approximately 1,200 new freemium creators joining every day. In December 2020, Vocal+ reached 10,000 paid subscribers, a 117% increase since the start of that quarter. “These updates, the first of many on our 2021 product roadmap, are focused on improving the way we champion and curate quality stories from Vocal’s creator community, said Creatd founder, president and head of product Justin Maury in the press release. “They also lay the foundation for exponential conversion growth across the platform.”
To view the full press release, visit https://ibn.fm/JJ0sG
About Creatd Inc.
Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about the company, please visit www.Creatd.com.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced that it has signed a three-year licensing agreement with Cup of Cosmo Studio (Beijing) Culture Co., Ltd. The agreement enables BHAT to use Cup of Cosmo Studio’s WUHUANGWANSHUI intellectual property (“IP”) on social media, toys and marketing materials, effective January 1, 2021. WUHUANGWANSHUI is an original Chinese cartoon and consisting of an image brand set of a cat (Wu Huang) and a dog (Ba Zahey). The brand is easily recognized in Chinese pop culture. “We are pleased to be partnering with Cup of Cosmo Studio with this licensing agreement for their famed WUHUANGWANSHUI brand, which we are confident will increase Blue Hat’s exposure and attract the attention of more potential customers. We expect this collaboration to serve as a catalyst for our business development efforts and strengthen our brand recognition,” Blue Hat CEO Xiaodong Chen stated in the news release.
To view the full press release, visit https://ibn.fm/FnHKu
About Blue Hat
Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick-and-mortar space has combined its patent-pending tech with major cryptocurrency payments to reach a significant milestone. The company announced that it had integrated Bitcoin, Ethereum and Litecoin into its contactless payments platform for use by retail customers and enterprise partners. The timing of this accomplishment is ideal as cryptocurrency payments are seeing a major paradigm shift toward global acceptance. The announcement marks the completion of the initial integration, which began in 2018; patents were filed in 2019, and the company has waited for moment when global commerce and regulatory acceptance of cryptocurrency payments created the greatest opportunity for success. “Whereas many companies try to use cryptocurrencies as a buzz word, Loop has been way ahead of this global paradigm shift to the delight of our customers and partners who want be ahead of what we anticipate being a parabolic growth decade for cryptocurrency transactions and payments,” said Loop Insights CEO Rob Anson in the press release. “Our Fobi device is already configured to accept leading cryptocurrencies including Bitcoin, Ethereum, and Litecoin, providing retailers with new long-term opportunities for growth and Enterprise partners with an even stronger value proposition that already includes our world-leading artificial intelligence-driven, real-time transaction technology.”
To view the full press release, visit http://ccw.fm/HqCN3
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. RACMF’s ability to integrate seamlessly into existing infrastructure and customize campaigns according to each vertical creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality and retail industries in Canada, the United States, the UK, Latin America, Australia, Japan and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information about the company, please visit www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About CryptoCurrencyWire (“CCW”)
CryptoCurrencyWire (CCW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with CCW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, CCW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CCW brings its clients unparalleled visibility, recognition and brand awareness.
To receive instant SMS alerts, text CRYPTO to 77948 (U.S. Mobile Phones Only)
CryptoCurrency News Wire is where News, content and information converge via Crypto.
For more information, please visit https://www.CryptoCurrencyWire.com
Please see full terms of use and disclaimers on the CryptoCurrencyWire (CCW) website applicable to all content provided by CCW, wherever published or re-published: http://CCW.fm/Disclaimer
CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
Editor@CryptoCurrencyWire.com
CryptoCurrencyWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced an additional order that came from a private company conducting research on ovarian cancer. Experts forecast that the 3D cancer cell culture media market will grow at CAGR of approximately 11.3%, reaching $3.2 billion in sales in worldwide by 2027. According to the announcement, the reason for the significant growth is because older technologies do not generally reproduce a patient’s tumor cell populations, and immortalized cells, or cells that live forever and are altered from the original tumor, do not make good models for use in drug discovery and development. The company called the idea of replicating ovarian cancer cells outside of a patient’s body and in a laboratory well plate or culture flask remarkable. “We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said POAI president and CEO Dr. Carl Schwartz in the press release. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step. Then we can focus on how to kill them.”
To view the full press release, visit https://ibn.fm/8LIzH
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Shares of iClick Interactive Asia Group Limited (NASDAQ:ICLK) traded today at $12.00, eclipsing its 52-week high. Approximately 253,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares.
iClick Interactive Asia Group Ltd is an independent online marketing and enterprise data solutions provider in China. It serves as an integrated cross-channel gateway that provides marketers with innovative and cost-effective ways to optimize their online marketing efforts throughout their marketing cycle and achieve their branding and performance-based marketing goals. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives majority revenue from PRC and also has a presence in Hong Kong and other countries.
iClick Interactive Asia Group Limited share prices have moved between a 52-week high of $12.00 and a 52-week low of $3.01 and are now trading 286% above that low price at $11.61 per share.
iClick Interactive Asia Group Limited (NASDAQ:ICLK) defies analysts with a current price ($11.61) 30.7% above its average consensus price target of $8.04.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent progress on planned clinical trials focusing on the treatment of non-small cell lung cancer. Genprex president and CEO Rodney Varner will deliver the presentation to participating investors. The Genprex presentation is scheduled for Tuesday, Jan. 19, at 3:45 p.m. EST. A replay of the presentation will be available on the company’s website and in a catalog of all NobleCon17 presentations to be rebroadcast on Channelchek.
To register for the event, visit https://ibn.fm/C5HbI
To view the full press release, visit https://ibn.fm/01koH
About Genprex Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
LAKEWOOD, Colo. , Jan. 14, 2021 – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) , a leading producer of uranium and critical minerals in the United States , is pleased to announce that the Company’s President and CEO Mark S. Chalmers will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 10:30 AM (EST) . The conference is virtual, with no cost, obligation or restrictions to attend: www.nobleconference.com .
Mr. Chalmers will provide an update on Energy Fuels’ various uranium and critical mineral initiatives, with particular emphasis on the Company’s progress on producing rare earth elements.
A high-definition, video webcast of the presentation will be available the following day on the Company’s website at www.energyfuels.com , and as a part of a complete catalog of presentations to be rebroadcast on Channelcheck ( www.channelchek.com ) next month.
About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U 3 O 8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado , near Denver , and all of its assets and employees are in the United States . Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah , the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming , and the Alta Mesa ISR Project in Texas . The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U 3 O 8 per year, has the ability to produce vanadium when market conditions warrant, and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U 3 O 8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U 3 O 8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com .
About Noble Capital Markets : Noble Capital Markets (“Noble”) is a research driven boutique investment bank that has supported small & micro-cap companies since 1984. As a FINRA and SEC licensed and registered broker-dealer, Noble provides institutional-quality equity research, merchant and investment banking, wealth management and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade+. In 2018, Noble launched www.channelchek.com – an investment community dedicated exclusively to small and micro-cap companies and their industries. Channelcheck is tailored to meet the needs of self-directed investors and financial professionals and is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 emerging growth companies are listed in the site, with growing content including webcasts, industry sector reports, advanced market data and balanced news.
Cautionary Note Regarding Forward-Looking Statements: This news release contains certain “Forward-Looking Information” and “Forward-Looking Statements” within the meaning of applicable United States and Canadian securities legislation, which may include, but are not limited to, statements with respect to any expectations regarding: the Company being a leading producer of uranium and critical minerals in the United States ; various uranium and critical mineral initiatives of the Company; and the Company’s progress on producing rare earth elements . Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects,” “does not expect,” “is expected,” “is likely,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates,” “does not anticipate,” or “believes,” or variations of such words and phrases, or state that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” “be achieved” or “have the potential to.” All statements herein, other than statements of historical fact, are considered to be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance of or achievements of the Company to be materially different from any future results, performance, or achievements, express or implied, by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: the Company being a leading producer of uranium and critical minerals in the United States ; various uranium and critical mineral initiatives of the Company; the Company’s progress on producing rare earth elements ; and the other factors described under the caption “Risk Factors” in the Company’s most recently filed Annual Report on Form 10-K, which is available for review on EDGAR at www.sec.gov/edgar.shtml , on SEDAR at www.sedar.com , and on the Company’s website at www.energyfuels.com . Forward-looking statements contained herein are made as of the date of this news release, and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or as a result of changes in management’s estimates or opinions, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. The Company assumes no obligation to update the information in this communication, except as otherwise required by law.
Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced the signing of a pilot agreement with PharmAssist Solutions to implement Loop’s analytics platform into multiple independent pharmacy affiliated locations. “Loop Insights data analytics solution is a game-changer for independent pharmacies here in the UK. PharmAssist Solutions has been integral to the success of the independent chain, and adding Loop’s ability to understand transaction details, shopping behaviors and habits, trends, and other powerful pieces of information once thought lost, will provide a massive benefit to each individual pharmacy,” Pharmassist Managing Director Amar Randhawa stated. “Understanding what products have been sold and prescribed gives these independents the ability to offer personal, relevant, and adjacent over the counter products to consumers, increasing sales, and delivering a more personal experience in-store. We are excited to be the first solutions provider in the UK market to offer this, and expect great uptake of the solution to our growing customer base.”
To view the full press release, visit http://ibn.fm/BF223
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information, visit the company’s website at www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Following the success of the Venue Bubble and Travel Bubble projects, Loop has partnered with Draganfly Inc. to launch the first Film Bubble for a major motion picture in January 2021
- The film and television industry has seen a significant drop in revenue, and the Film Bubble is positioned to make sets safer with the technology provided by Draganfly
- Effective December 11, 2020, Mark Lotz took over the position of Chief Financial Officer after the resignation of Abbey Abdiye
Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), an innovative Internet of Things (“IoT”) technology company that delivers contactless solutions, including venue management, personalized engagement, and AI-driven insights, is partnering with Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8)) to launch the first “Film Bubble,” a solution designed to help keep movie sets safer and operational during the coronavirus pandemic (https://ibn.fm/tJAKt).
The Film Bubble provides another major opportunity for Loop as a spin-off of the recently successful NCAA Venue Bubble and Travel Bubble projects. According to Loop CEO Rob Anson, the Film Bubble will provide a great showcase for the company’s film industry solution as well as additional opportunities for travel, venue, and other healthcare applications Loop Insights has been working on.
The Film Bubble will be launched for a major motion picture scheduled to commence filming in January 2021. At this time, the names of the motion picture and the actors are being kept confidential until filming begins.
Under the partnership agreement, Loop Insights and Draganfly will combine technologies into Loop’s Venue Bubble solution with the ultimate goal of making the film and television industry safer to resume production, resulting in higher revenue and employment opportunities. “Film industry investors, insurance companies, unions, and guilds are all seeking this type of solution to keep workers safe and protect their investments,” Draganfly CEO Cameron Chell said.
Draganfly provides Safe Set Solutions for the global film and television production industry using ground-based technology for symptom pre-screening, elevated body temperature measurement, and social distancing display.
The Film Bubble solution comes at the right time for an industry that has reported billions in losses as a result of the coronavirus pandemic closing down movie theaters and production. In 2019, the North American box office amounted to $11.32 billion in total earnings and employed over 456 thousand people with several hundred thousand more employees in Canada and other countries worldwide (https://ibn.fm/hVmFz). This past November, AMC Theatres announced that they had seen a 91% drop in their revenues during the most recent earnings period resulting in a loss of $906 million in this quarter alone. The overall global entertainment industry is also projected to lose $160 billion of growth over the next five years (https://ibn.fm/Kr0Wj).
“The addition of Draganfly’s Safe Set Solutions to our Venue Bubble Platform creates an instant and powerful Film Bubble solution for an industry that has suffered catastrophic losses in 2020 and can’t afford to stay shut down for a minute longer,” Anson said. “We are extremely proud to have jointly delivered a solution to the film industry that will allow them to safely get their crews, actors, and supporting infrastructure back to work and generating prosperity, the ripple effects of which reverberate around the world.”
On the same day the Film Bubble partnership was made public, Loop Insights announced the appointment of a new Chief Financial Officer. The previous CFO, Abbey Abdiye, resigned from the company to pursue other career opportunities. He is replaced by Mark Lotz, who took over the position effective December 11, 2020 (https://ibn.fm/Vicrd). Lotz is a Chartered Professional Accountant with 26 years of post-qualification experience. His experience spans across a broad cross-section of industries that include SaaS, mining, manufacturing, financial service, and technology. Lotz has a Bachelor’s degree in Business Administration with a dual Economics major.
Backed by Amazon’s Partner Network, Loop has developed a line of powerful technologies that are simple to use but designed to transform industries. Fobi, an IoT device that is designed to seamlessly integrate with any existing point of sale infrastructure, collects 100% of the transactional data and sends it to the cloud. SmarTap is Loop’s Near Field Communication (“NFC”) device that enables consumers to check-in using a “tap” and their smartphone’s NFC compatibility. SmarTap offers a contactless consumer experience and connects with the cloud via LTE or WiFi to securely transmit data.
Loop Cloud is the middle ground where Fobi and SmarTap’s information meets, being stored digitally and creating a database for the company and their clients. When paired with either Loop solution, the Loop Cloud creates a way for the business to transform their edge-based legacy systems into a unified database.
For more information, visit the company’s website at www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, priced at-the-market under Nasdaq rules. Predictive Oncology secured $3.074 million in gross proceeds from the offering. In a concurrent private placement, Predictive Oncology also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,825,420 shares of common stock at an exercise price of $0.80 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
To view the full press release, visit http://ibn.fm/IV2JI
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA approval to begin clinical trials studying the company’s lead drug candidate, Berubicin. CNSP is developing Berubicin as a potential treatment for glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Climaco called Berubicin a “powerhouse compound” and said the FDA approval was a big day for GBM patients, which is a population that has seen little innovation for the past 15 years. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said in the press release. “The FDA approved an Investigational New Drug application, which allows us to proceed with our clinical trial. Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials for our lead compound, Berubicin, which is a novel treatment for glioblastoma, the most common and aggressive form of primary brain cancer. . . . If you get GBM, the sad reality is you’re probably going to die from it. We think we can change that game.”
To hear the full podcast, visit http://ibn.fm/IDQi3
To view the full press release, visit http://ibn.fm/ZdFo5
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers
- Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain
- The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024
- CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin
CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, including the use of Berubicin for patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently working on the development and clinical trials of Berubicin for GBM and the potential of addressing other central nervous system malignancies.
Berubicin appears to be the first anthracycline to cross the blood-brain barrier in the adult brain. Its development started over 15 years ago when Reata Pharmaceuticals, Inc. (NASDAQ: RETA) conducted the first Phase I trial, creating limited clinical data. Phase I trial results indicated that 44 percent of participants reported a significant improvement in the size of the tumor. The evidence concluded that there was a positive enough impact that CNS has continued with the development and the clinical-stage trials for the drug.
CNS holds the exclusive license for Berubicin worldwide. The company goes into the year 2021 determined to move forward with the development and distribution of Berubicin for GBM. The recent approval of the United States Food and Drug Administration (“FDA”) of Berubicin as an investigational new drug (“IND”) has only increased the opportunity for CNS to move forward with the three clinical trials currently in development.
“The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans (https://ibn.fm/TP3oE).
The company’s sublicensee WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1) will be conducting a Phase II trial in adults, as well as the first-ever Phase I trial in children who suffer from GBM and other cancers of the brain and central nervous system. This is the first pediatric trial of its kind.
According to Climaco, CNS aims to address the significant unmet medical need of GBM patients since the current treatment paradigm for the condition yields bleak results, and this aggressive and, as yet, incurable form of brain cancer continues to claim high mortality rates. “We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial,” he added.
The GBM treatments market is anticipated to increase to an estimated $3.3 billion in 2014, marking a CAGR of 17.4% from 2014, when the market was $659. The growth is expected to be driven by seven major markets – the United States, Spain, the UK, France, Italy, Japan, and Germany, and is the direct result of the growing unmet needs of the current market (https://ibn.fm/ZAYjM).
Berubicin is currently being produced in two labs as a result of a dual-track manufacturing strategy implemented by CNS. To ensure that current conditions do not hinder the progress of Berubicin’s development and availability, CNS has turned to United States-based Pharmaceuticals International Inc. and Italy-based BSP Pharmaceuticals SpA for the production of Berubicin for the clinical trials. Both pharmaceutical companies have diversified the supply chain, and increased the availability of Berubicin, mitigating the risks of COVID-19 in clinical trial strategies.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Company extends expiration of special dividend for one year
- If declared, special dividend will consist of number, designation determined by company management
- BIGtoken is first consumer-managed data marketplace where people can own, earn from their data
SRAX (NASDAQ: SRAX) will extend the expiration for its previously announced BIGtoken special dividend right for one year. The dividend right was set to expire on or before 5 p.m. on Dec. 31, 2020, and that deadline has been extended to on or before 5 p.m. ET on Dec. 31, 2021 (https://ibn.fm/sCKWJ).
The original dividend right was issued on Sept. 17, 2018, when SRAX, then called Social Reality Inc., announced a nontransferable right to receive at no charge a special dividend to holders of the company’s Class A common stock; the right was also extended to certain holders of the company’s common stock equivalents.
The extension announcement notes that “if and when declared, the Special Dividend will consist of such number and designation of the SRAX subsidiary BIGtoken Inc.’s securities as determined by the company’s management at their sole discretion. . . . The Special Dividend will be an analog security, i.e., not digital, and not a cryptocurrency, and the Special Dividend is expected to be a fractional non-voting security that, if and when issued, is expected to only participate in a portion of the financial performance of the BIGtoken platform.”
Initially launched by SRAX and then spun off as a separate company, BIGtoken, or BIG, is a secure consumer data-management and distribution system —the first consumer-managed data marketplace where people can own and earn from their data (https://ibn.fm/nr4Sm). Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participants earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform (https://ibn.fm/Ol2Qb).
At last count, BIGtoken has compensated more than 16 million users for access to their data while creating data sets across 25,000 unique market segments. Brands are offered access to this verified, opted-in data for a fee.
“BIGtoken is a secure platform that empowers you to realize and claim the value of your digital self,” the website observes (https://ibn.fm/B0Cj3). “You have a right to privacy, awareness, and choice when it comes to the data you put out into the digital world. With BIG, you can own and earn from that data while staying connected to your community.”
SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 1 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike.
For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
